Introduction {#s1}
============

Chronic kidney disease (CKD) has become a serious threat to human health worldwide [@pone.0084688-Levey1]. Increasing prevalence of diabetes, hypertension, and obesity will result in an even greater burden of CKD in developing countries such as China [@pone.0084688-Nugent1]. In *The Lancet*, Zhang et al. presented the results of the first comprehensive study exploring the prevalence of CKD in China. The prevalence was 10.8% in 2012, equivalent to 119.5 million CKD patients [@pone.0084688-Zhang1]. Outcomes of CKD include not only progression to kidney failure but also a series of complications [@pone.0084688-Levey2]. Early impaired kidney function often has no obvious symptoms, which leads to easily missed or delayed diagnosis. Therefore, accurate assessment of kidney function is essential, which needs not only the public awareness of termly medical examination, but also a simple method to assess the kidney function. Due to the invasiveness, inconveniency and high cost, measuring GFR by the clearance of some exogenous markers is unsuitable in routine clinical practice, although they are the gold-standard methods [@pone.0084688-Stevens1]. Under such circumstance, estimating equations of GFR have gained booming development.

Among a large number of variations, the Modification of Diet in Renal Disease (MDRD), serum creatinine-based Chronic Kidney Disease Epidemiology Collaboration (hereafter referred to as CKD-EPI~2009Scr~) and MacIsaac equations have been publicly approved and applied [@pone.0084688-Pei1]. Ma et al. developed the Chinese adapted MDRD equation (hereafter referred to as C-MDRD), which was validated to be better than other MDRD equations in Chinese subjects [@pone.0084688-Ma1]. However, in patients with near-normal kidney function, the MDRD equations underestimate GFR [@pone.0084688-Zuo1]. The CKD-EPI~2009Scr~ equation partly overcomes the major limitation of the MDRD equation [@pone.0084688-Levey3]. The MacIsaac equation is a typical cystatin C-based equation developed in 2006. The investigators challenged the traditional view that cystatin C level was independent of body composition. They proved that accounting for body composition improved cystatin C-based GFR estimation [@pone.0084688-Macdonald1]. Some researchers shifted their focus to equations based on combination of different markers, for example, the combination of serum creatinine and cystatin C [@pone.0084688-Bouvet1]. Ma equation is a representative, which is also based on the data from the Chinese population. They found the equation performed better than the C-MDRD equation, especially in early detection of CKD [@pone.0084688-Ma2]. Our previous work evaluated the performance of existing equations, showing that they have their own applicability in different CKD stages and age groups [@pone.0084688-Pei2].

Recently, the CKD-EPI working group has reported two new CKD-EPI equations: one using cystatin C concentration (CKD-EPI~2012cys~) and the other using both cystatin C and serum creatinine concentrations (CKD-EPI~2012Scr-cys~). They validate the new equations represent an advance over currently available equations across the range of GFR and in relevant subgroups. The advance even holds true among participants with an extreme body-mass index (the weight in kilograms divided by the square of the height in meters) of less than twenty [@pone.0084688-Inker1]. The two new equations even have been recommended by KDIGO 2012Clinical Practice Guidelines for the Evaluation and Management of CKD [@pone.0084688-Kidney1]. A series of research for validation of the new formulae has appeared. Mindikoglu et al. evaluated the performance of CKD-EPI~2012Scr-cys~ equation in subjects with cirrhosis, claiming that it was superior to conventional equations for estimating GFR; however, the diagnostic performance was not as good as reported in non-cirrhotic subjects [@pone.0084688-Mindikoglu1]. Obiols et al. found CKD-EPI~2012Scr-cys~ equation was more accurate and precise in hypertensive patients with higher GFR [@pone.0084688-Obiols1]. Kilbride et al. tested the accuracy of the new equations in old people in London [@pone.0084688-Kilbride1]. Few data were available in China about the comparison of new equations with other traditional formulae. We compared the adaptability of new formulae with other four equations.

Materials and Methods {#s2}
=====================

Participants {#s2a}
------------

Totally 788 Chinese participants older than 18 years, with or without CKD at the First Affiliated Hospital of Nanjing Medical University between December 2009 and March 2012, were consecutively enrolled in the study. All participants in this study signed the informed consent. The ethics committee of Nanjing Medical University approved the study.

The participants with severe heart failure, acute renal failure, pleural or abdominal effusion, serious edema or malnutrition, skeletal muscle atrophy, amputation, ketoacidosis were excluded. Patients who were taking trimethoprim or cimetidine or ACEI/ARB and those who had recently received glucocorticoid and hemodialysis therapy were also excluded.

Measurement and Estimation of GFR {#s2b}
---------------------------------

Patients were informed in advance to avoid any meat consumption on the day of the test. Demographic data and past history were recorded and blood pressure, weight, and height were documented. Serum creatinine (Scr) concentration was assayed by the enzymatic method (Shanghai Kehua Dongling Diagnostic Products Co., Ltd, China), traceable to National Institute of Standards and Technology creatinine standard reference material (SRM 967).Cystatin C concentration was examined by the particle-enhanced immunoturbidimetry method (Beijing Leadman Biomedical Co., Ltd, China),which was calibrated against the international certified reference material ERM-DA471. Both fasting serum samples were assayed on an Olympus AU5400 autoanalyser (Olympus Co., Japan), in strict accordance with the manufacturer\'s instructions.

All participants had a ^99^mTc-DTPA renal dynamic imaging measurement as the reference glomerular filtration rate (rGFR), who had been required to have no special change in diet. After measuring height and weight, drinking300 ml water, and emptying the bladder, participants received a bolus injection in the elbow vein of 185 MBq 99mTc-DTPA (purity 95%--99%, Nanjing Senke Co., Ltd, China). The ^99^mTc-DTPA renal dynamic imaging measurement was carried out and after images acquisition, rGFR was automatically calculated with a computer by the Gates method.

Estimated glomerular filtration rate (eGFR) was calculated separately from six GFR estimating equations including the C-MDRD, MacIsaac equation, Ma equation, CKD-EPI~2009Scr~, CKD-EPI~2012cys~ and CKD-EPI~2012Scr-cys~ equations. The results are presented in detail in [Table 1](#pone-0084688-t001){ref-type="table"}.

10.1371/journal.pone.0084688.t001

###### Equations to predict glomerular filtration rate.

![](pone.0084688.t001){#pone-0084688-t001-1}

  Name                    Year   Gender    Scr    Scys                                  Equation
  ---------------------- ------ -------- ------- ------- -----------------------------------------------------------------------
  C-MDRD                  2006                                        175×Scr^−1.234^×age^−0.179^(×0.79,if female)
  MacIsaac                2006                                                       (86.7/Scys)-4.2
  Ma                      2007                                  169×Scr^−0.608^×Scys^−0.63^×age^−0.157^(×0.83,if female)
  CKD-EPI~2009Scr~        2009   female   ≤0.7                     144× (Scr/0.7)^−0.329^×0.993^age^(×1.159,if black)
                                          \>0.7                    144× (Scr/0.7)^−1.209^×0.993^age^(×1.159,if black)
                                  male    ≤0.9                     141× (Scr/0.9)^−0.411^×0.993^age^(×1.159,if black)
                                          \>0.9                    141× (Scr/0.9)^−1.209^×0.993^age^(×1.159,if black)
  CKD-EPI~2012cys~        2012   female           ≤0.8                  133× (Scys/0.8)^−0.499^×0.996^age^×0.932
                                                  \>0.8                 133× (Scys/0.8)^−1.328^×0.996^age^×0.932
                                  male            ≤0.8                     133× (Scys/0.8)^−0.499^×0.996^age^
                                                  \>0.8                    133× (Scys/0.8)^−1.328^×0.996^age^
  CKD-EPI~2012Scr-cys~    2012   female   ≤0.7    ≤0.8    130× (Scr/0.7)^−0.248^× (Scys/0.8)^−0.375^×0.995^age^(×1.08,if black)
                                                  \>0.8   130× (Scr/0.7)^−0.248^× (Scys/0.8)^−0.711^×0.995^age^(×1.08,if black)
                                          \>0.7   ≤0.8    130× (Scr/0.7)^−0.601^× (Scys/0.8)^−0.375^×0.995^age^(×1.08,if black)
                                                  \>0.8   130× (Scr/0.7)^−0.601^× (Scys/0.8)^−0.711^×0.995^age^(×1.08,if black)
                                  male    ≤0.9    ≤0.8    135× (Scr/0.9)^−0.207^× (Scys/0.8)^−0.375^×0.995^age^(×1.08,if black)
                                                  \>0.8   135× (Scr/0.9)^−0.207^× (Scys/0.8)^−0.711^×0.995^age^(×1.08,if black)
                                          \>0.9   ≤0.8    135× (Scr/0.9)^−0.601^× (Scys/0.8)^−0.375^×0.995^age^(×1.08,if black)
                                                  \>0.8   135× (Scr/0.9)^−0.601^× (Scys/0.8)^−0.711^×0.995^age^(×1.08,if black)

Note: Scr was shown as mg/dL; Scys was shown as mg/L; age was shown as years.

Abbreviations: Scr: serum creatinine; Scys: serum cystatin C; C-MDRD: the Chinese modified Modification of Diet in Renal Disease equation; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; CKD-EPI~2009Scr~: serum creatinine--based CKD-EPI equation which was developed in 2009; CKD-EPI~2012cys~: cystatin C--based CKD-EPI equation which was newly developed in 2012; CKD-EPI~2012Scr-cys~: serum creatinine-- and cystatin C--based CKD-EPI equation which was newly developed in 2012.

Statistical Analysis {#s2c}
--------------------

No data sets were normally distributed (P\<0.001, Kolmogorov-Smirnov test); thus, nonparametric statistics were used throughout. The receiver operating characteristic (ROC) curve was depicted to analyse the diagnostic value of 6 equations. Abscissa of the curve is the value of (1- specificity) and the vertical is sensitivity. The larger area under the ROC curve (ROC^AUC^) usually means a better diagnostic value. Bias, precision and accuracy were used to evaluate the performance of each equation. Bias was defined as the median results of differences between eGFR and rGFR (eGFR-rGFR). The interquartile range (IQR) of the differences was a marker of precision. Accuracy was calculated as the proportion of eGFR within 30% of rGFR (P~30~) and also as root mean square error (RMSE). Wilcoxon matched-pairs signed rank test was used to compare the bias of each eGFR against rGFR. McNemar test was used to compare P~30~ values of the C-MDRD, MacIsaac, Ma, CKD-EPI~2012cys~ and CKD-EPI~2012Scr-cys~ equations against the P~30~ value of the CKD-EPI~2009Scr~ equation.

Bias plots were used to compare eGFR with rGFR intuitively. The difference between eGFR and rGFR was regressed against the mean of rGFR and eGFR. The greater slope of regression line against the x-axis means the larger bias. The larger intercept of the regression line against the y-axis indicates poorer accuracy. Kappa test was used to compare the diagnosis consistency of GFR stage between the eGFR and mGFR: kappa value 0.21--0.40 is considered mild agreement, 0.41--0.60 moderate agreement, 0.61--0.80 substantial agreement and 0.81--1.00 near-perfect agreement. Data was considered statistically significant at p\<0.05. All statistical analyses were performed using SPSS software (version 17.0; SPSS, Chicago, IL, USA), Epical software (version 1.01; EpiCalc 2000 Application, Brixton Books, USA) and Medcalc for Windows (version 11.6.1.0; Medcalc Software, Mariekerke, Belgium).

Results {#s3}
=======

Participant characteristics {#s3a}
---------------------------

A total of 788 participants (478 male and 310 female), with or without CKD were enrolled. Median rGFR, cystatin C and Scr were 76.35 (interquartile range, 59.03--92.50) mL/min/1.73 m^2^, 1.09 (interquartile range, 0.92--1.43) mg/L and 0.94(interquartile range, 0.74--1.22) mg/dL, respectively. Participants were divided into two groups with rGFR\<60 and ≥60 mL/min/1.73 m^2^ and also divided into two groups with age \<60 and ≥60 years old. The detailed laboratory and anthropometric measurements are shown in [Table 2](#pone-0084688-t002){ref-type="table"}.

10.1371/journal.pone.0084688.t002

###### Characteristics of the Study Population.
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                                All subjects             Age\<60                Age≥60
  ------------------------ ---------------------- ---------------------- ---------------------
  Age(years)                     54(41--65)             45(34--53)            69(64--75)
  Gender                                                                 
  Male                           478(60.70)             298(59.60)             180(62.5)
  Female                         310(39.30)             202(40.40)             108(37.5)
  Weight(kg)                     65(55--69)             65(55--68)            65(56--70)
  Height(m)                   1.69(1.60--1.70)       1.70(1.60--1.70)      1.68(1.60--1.70)
  BSA(m^2^)                   1.74(1.57--1.79)       1.73(1.56--1.78)      1.75(1.60--1.79)
  BMI(kg/m^2^)              22.49(21.48--24.49)    22.49(21.48--24.22)    22.49(21.48--24.89)
  BUN(mmol/L)                 5.75(4.52--7.54)       5.33(4.17--6.78)      6.74(5.29--9.22)
  Scr(mg/L)                   0.94(0.74--1.22)       0.85(0.68--1.06)      1.09(0.88--1.51)
  Scys(mg/L)                  1.09(0.92--1.43)       0.98(0.84--1.20)      1.34(1.10--1.93)
  rGFR(mL/min/1.73 m^2^)    76.35(59.03--92.50)    85.35(70.83--100.45)   62.85(46.35--74.85)
  GFR category                                                           
  ≥60 mL/min/1.73 m^2^           584(74.11)             425(85.00)            159(55.21)
  \<60 mL/min/1.73 m^2^          204(28.59)             75(15.00)             129(44.79)
  eGFR(mL/min/1.73 m^2^)                                                 
  C-MDRD                    87.27(62.91--111.25)   99.39(75.78--123.62)   66.35(45.24--85.99)
  MacIsaac                  73.99(54.88--89.50)    82.58(66.33--96.75)    58.30(40.50--73.80)
  Ma                        84.82(58.92--107.25)   96.61(76.16--116.41)   63.31(41.15--80.31)
  CKD-EPI~2009Scr~          83.57(58.90--102.16)   95.82(76.18--110.28)   61.22(41.19--78.68)
  CKD-EPI~2012cys~          67.75(45.62--90.63)    81.71(61.19--99.22)    47.57(30.45--64.65)
  CKD-EPI~2012Scr-cys~      75.80(51.41--94.67)    88.00(69.42--103.28)   54.06(34.45--70.38)
  Comorbid conditions                                                    
  Nephritis                       46(5.84)               28(5.60)              18(6.25)
  Kidney neoplasm                221(28.04)             132(26.40)             89(30.90)
  Hematological disease          111(14.09)             101(20.20)             10(3.47)
  Hypertension                   162(20.56)             70(14.00)              92(31.94)
  Coronary heart disease          35(4.44)               7(1.40)               28(9.72)
  Diabetic mellitus              84(10.66)               26(5.20)              58(20.14)

Note: Values for continuous variables expressed as median (inter-quartile range); values for categorical values expressed as number (percentage). Conversion factors for units: serum creatinine in mg/dL to µmol/L, ×88.4.

Abbreviations: BSA: body surface aera; BMI: body mass index; Scr: serum creatinine; Scys: serum cystatin C; rGFR: reference glomerular filtration rate (using the ^99^mTc-DTPA renal dynamic imaging method); eGFR: estimated glomerular filtration rate; C-MDRD: the Chinese modified Modification of Diet in Renal Disease equation; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; CKD-EPI~2009Scr~: serum creatinine--based CKD-EPI equation which was developed in 2009; CKD-EPI~2012cys~: cystatin C--based CKD-EPI equation which was newly developed in 2012; CKD-EPI~2012Scr-cys~: serum creatinine-- and cystatin C--based CKD-EPI equation which was newly developed in 2012.

Performance of six equations in all participants {#s3b}
------------------------------------------------

Compared with CKD-EPI~2009Scr~, CKD-EPI~2012Scr-cys~ equation had a larger ROC^AUC^ (0.879 vs. 0.845) and higher sensitivity (88.7% vs.77.0%) but lower specificity (87.2% vs.92.1%) to diagnose CKD. CKD-EPI~2012cys~ equation did not perform much better than other available equations, except for its sensitivity ([Table 3](#pone-0084688-t003){ref-type="table"}).

10.1371/journal.pone.0084688.t003

###### Diagnostic value of six estimating equations compared with rGFR.

![](pone.0084688.t003){#pone-0084688-t003-3}

  All subjects                    R                 ROC^AUC^         sensitivity   specificity
  ---------------------- -------------------- --------------------- ------------- -------------
  C-MDRD                  0.795(p~1~ = 0.9)     0.853(p~2~ = 0.4)       75.5          95.0
  MacIsaac                0.789(p~1~ = 0.6)     0.866(p~2~ = 0.1)       84.8          88.4
  Ma                      0.828(p~1~ = 0.08)    0.860(p~2~ = 0.1)       78.9          93.0
  CKD-EPI~2009Scr~              0.798                 0.845             77.0          92.1
  CKD-EPI~2012cys~        0.802(p~1~ = 0.8)     0.852(p~2~ = 0.7)       92.2          78.3
  CKD-EPI~2012Scr-cys~    0.829(p~1~ = 0.07)   0.879(p~2~ = 0.006)      88.7          87.2

  age\<60 y                       R                 ROC^AUC^         sensitivity   specificity
  ---------------------- -------------------- --------------------- ------------- -------------
  C-MDRD                  0.671(p~1~ = 0.8)    0.851(p~2~ = 0.05)       73.3          96.9
  MacIsaac                0.673(p~1~ = 0.7)     0.862(p~2~ = 0.1)       78.7          93.6
  Ma                      0.720(p~1~ = 0.07)    0.851(p~2~ = 0.1)       73.3          96.9
  CKD-EPI~2009Scr~              0.661                 0.829             69.3          96.5
  CKD-EPI~2012cys~        0.681(p~1~ = 0.6)    0.876(p~2~ = 0.06)       86.7          88.5
  CKD-EPI~2012Scr-cys~    0.718(p~1~ = 0.09)   0.883(p~2~ = 0.005)      81.3          95.3

  age≥60 y                        R                ROC^AUC^         sensitivity   specificity
  ---------------------- ------------------- --------------------- ------------- -------------
  C-MDRD                  0.804(p~1~ = 0.9)    0.833(p~2~ = 0.1)       76.7          89.9
  MacIsaac                0.807(p~1~ = 0.9)    0.813(p~2~ = 0.9)       88.4          74.2
  Ma                      0.832(p~1~ = 0.4)    0.823(p~2~ = 0.3)       82.2          82.4
  CKD-EPI~2009Scr~              0.806                0.809             81.4          80.5
  CKD-EPI~2012cys~        0.807(p~1~ = 0.9)   0.731(p~2~ = 0.002)      95.3          50.9
  CKD-EPI~2012Scr-cys~    0.834(p~1~ = 0.3)    0.792(p~2~ = 0.4)       93.0          65.4

Note: R =  coefficient of relationship between eGFR and rGFR; ROC^AUC^  =  aera under receiver operating characteristic curve.

Abbreviations: C-MDRD: the Chinese modified Modification of Diet in Renal Disease equation; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; CKD-EPI~2009Scr~: serum creatinine--based CKD-EPI equation which was developed in 2009; CKD-EPI~2012cys~: cystatin C--based CKD-EPI equation which was newly developed in 2012; CKD-EPI~2012Scr-cys~: serum creatinine-- and cystatin C--based CKD-EPI equation which was newly developed in 2012.

Correlation coefficients of the C-MDRD equation, MacIsaac equation, Ma equation, CKD-EPI~2012cys~ equation and CKD-EPI~2012Scr-cys~ equation were compared against that of CKD-EPI~2009Scr~ equation (p~1~).

ROC^AUC^ of the C-MDRD equation, MacIsaac equation, Ma equation, CKD-EPI~2012cys~ equation and CKD-EPI~2012Scr-cys~ equation were compared against that of CKD-EPI~2009Scr~ equation (p~2~).

Performance of the equations is summarized in [Table 4](#pone-0084688-t004){ref-type="table"}, and bias plots of the 6 equations against rGFR are shown in [Figure 1](#pone-0084688-g001){ref-type="fig"}. Both CKD-EPI~2012Scr-cys~ and CKD-EPI~2012cys~ underestimated GFR \[(bias, −4.11; 95%CI, −5.17to−2.29 mL/min/1.73 m^2^; P\<0.001) and (bias, −9.23; 95%CI, −10.60 to−7.40 mL/min/1.73 m^2^; P\<0.001,) respectively\] in the whole cohort. CKD-EPI~2009Scr~, Ma and C-MDRD equations overestimated GFR. Of all the 6 equations, CKD-EPI~2009Scr~ possessed the smallest difference (bias, 2.21; 95%CI, 0.73to4.58 mL/min/1.73 m^2^; P\<0.001). MacIsaac, CKD-EPI~2012Scr-cys~ and CKD-EPI~2009Scr~ equation appeared to be more accurate with higher P~30~ value (80.20%, 77.03% and 75.76%, respectively).CKD-EPI~2012cys~ equation performed not as well as previously expected (P~30~ value, 68.40%). Concurrently, CKD-EPI~2012Scr-cys~ equation had the lowest RMSE and relative lower IQR.

![Bias plots intuitively compare estimated glomerular filtration rate (eGFR) with reference glomerular filtration rate (rGFR).\
The difference between eGFR and rGFR was regressed against the mean of rGFR and eGFR. The eGFRs were calculated separately from six estimating equations. (A) C-MDRD: the Chinese modified Modification of Diet in Renal Disease equation; (B) MacIsaac equation; (C) Ma equation; (D) CKD-EPI~2009Scr~: serum creatinine--based CKD-EPI equation which was developed in 2009; (E) CKD-EPI~2012cys~: cystatin C--based CKD-EPI equation which was newly developed in 2012; (F) CKD-EPI~2012Scr-cys~: serum creatinine-- and cystatin C--based CKD-EPI equation which was newly developed in 2012. GFR were measured in mL/min/1.73 m^2^. Horizontal solid lines represent zero bias. Horizontal dashed lines represent 25th percentiles bias, median bias and 75th percentiles of the bias.](pone.0084688.g001){#pone-0084688-g001}
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###### Performance of six estimating equations compared with rGFR.
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  All subjects            Bias (median difference) (95%CI)    Precision (IQR of the difference)        Accuracy P~30~ (95%CI)         Accuracy (RMSE)
  ---------------------- ----------------------------------- ----------------------------------- ----------------------------------- -----------------
  C-MDRD                    8.17(6.59,10.01)(p~3~\<0.001)                   32.11                  64.21(60.74,67.55)(p~4~\<0.001)         29.74
  MacIsaac                −4.08(−5.58, −2.77)(p~3~\<0.001)                  20.88                 80.20(77.21,82.90) (p~4~ = 0.02)         18.40
  Ma                        5.52(3.51,6.88)(p~3~\<0.001)                    28.01                 71.19(67.87,74.31) (p~4~ = 0.003)        22.81
  CKD-EPI~2009Scr~          2.21(0.73,4.58)(p~3~\<0.001)                    24.49                        75.76(72.58,78.68)                18.94
  CKD-EPI~2012cys~        −9.23(−10.60, −7.40)(p~3~\<0.001)                 24.39                  68.40(65.01,71.61)(p~4~\<0.001)         20.10
  CKD-EPI~2012Scr-cys~    −4.11(−5.17, −2.29)(p~3~\<0.001)                  23.84                  77.03(73.90,79.89)(p~4~ = 0.5)          17.29

  rGFR≥60 mL/min/1.73 m^2^    Bias (median difference) (95%CI)   Precision (IQR of the difference)        Accuracy P~30~ (95%CI)        Accuracy (RMSE)
  -------------------------- ---------------------------------- ----------------------------------- ---------------------------------- -----------------
  C-MDRD                       11.54(9.33,14.10)(p~3~\<0.001)                  32.36                 66.95(62.95,70.73) (p~4~\<0.001)        32.84
  MacIsaac                    −4.22(−5.94, −2.41)(p~3~\<0.001)                 23.12                  84.76(81.53,87.53)(p~4~ = 0.2)         20.06
  Ma                           8.80(6.71,10.79)(p~3~\<0.001)                   28.42                 73.63(69.82,77.12)(p~4~\<0.001)         25.07
  CKD-EPI~2009Scr~              4.99(2.30,7.31)(p~3~\<0.001)                   25.67                        81.68(78.25,84.68)               19.66
  CKD-EPI~2012cys~            −7.37(−9.89, −4.41)(p~3~\<0.001)                 27.89                 75.51(71.78,78.91)(p~4~ = 0.008)        21.30
  CKD-EPI~2012Scr-cys~         −1.48(−3.82,1.13)(p~3~ = 0.09)                  25.34                 85.45(82.26,88.15)(p~4~ = 0.03)         18.07

  rGFR\<60 mL/min/1.73 m^2^     Bias (median difference) (95%CI)     Precision (IQR of the difference)       Accuracy P~30~ (95%CI)        Accuracy (RMSE)
  --------------------------- ------------------------------------- ----------------------------------- --------------------------------- -----------------
  C-MDRD                          −0.22(−3.25,2.48)(p~3~ = 0.9)                    23.10                 56.37(49.27,63.23)(p~4~ = 0.4)         18.14
  MacIsaac                      −3.91(−5.81, −1.53)(p~3~\<0.001)                   17.01                 67.16(60.19,73.46)(p~4~ = 0.05)        12.47
  Ma                             −3.08(−5.33,0.67)(p~3~ = 0.03)                    19.05                 64.22(57.18,70.71)(p~4~ = 0.1)         14.51
  CKD-EPI~2009Scr~              −2.48(−5.45, −0.43)(p~3~ = 0.07)                   19.97                       58.82(51.72,65.59)               16.72
  CKD-EPI~2012cys~             −10.86(−13.38, −9.82) (p~3~\<0.001)                 16.29                 48.04(41.04,55.11)(p~4~ = 0.02)        16.20
  CKD-EPI~2012Scr-cys~          −8.07(−11.34, −5.37)(p~3~\<0.001)                  17.34                 52.94(45.86,59.91)(p~4~ = 0.2)         14.83

  age\<60 y               Bias (median difference) (95%CI)   Precision (IQR of the difference)        Accuracy P~30~ (95%CI)        Accuracy (RMSE)
  ---------------------- ---------------------------------- ----------------------------------- ---------------------------------- -----------------
  C-MDRD                   11.68(9.03,14.08)(p~3~\<0.001)                  35.06                 62.00(57.57,66.24)(p~4~\<0.001)         34.21
  MacIsaac                −3.21(−5.58, −1.25)(p~3~\<0.001)                 22.12                 80.60(76.80,83.92)(p~4~ = 0.05)         20.40
  Ma                       10.48(8.36,13.11)(p~3~\<0.001)                  30.42                 68.20(63.89,72.23)(p~4~\<0.001)         26.01
  CKD-EPI~2009Scr~          7.53(5.34,9.57)(p~3~\<0.001)                   26.19                        75.60(71.55,79.25)               21.01
  CKD-EPI~2012cys~        −4.55(−7.40, −2.82)(p~3~\<0.001)                 24.91                  75.40(71.34,79.07)(p~4~ = 0.1)         20.54
  CKD-EPI~2012Scr-cys~      1.60(−0.78,3.22)(p~3~ = 0.6)                   24.11                 82.00(78.29,85.21)(p~4~ = 0.001)        18.19

  age≥60 y                 Bias (median difference) (95%CI)     Precision (IQR of the difference)        Accuracy P~30~ (95%CI)        Accuracy (RMSE)
  ---------------------- ------------------------------------- ----------------------------------- ---------------------------------- -----------------
  C-MDRD                     3.01(1.14,5.86)(p~3~\<0.001)                     23.96                 68.06(62.28,73.34)(p~4~ = 0.001)        19.70
  MacIsaac                 −4.64(−6.91, −3.06)(p~3~\<0.001)                   19.42                  79.51(74.29,83.93)(p~4~ = 0.3)         14.28
  Ma                         0.54(−3.44,2.29)(p~3~ = 0.9)                     18.19                  76.39(70.97,81.09)(p~4~ = 1.0)         15.81
  CKD-EPI~2009Scr~         −2.66(−4.67, −0.85)(p~3~ = 0.007)                  18.01                        76.04(70.61,80.77)               14.66
  CKD-EPI~2012cys~        −14.16(−17.31, −11.05)(p~3~\<0.001)                 19.48                 56.25(50.30,62.03)(p~4~\<0.001)         19.31
  CKD-EPI~2012scr-cys~     −9.46(−11.39, −7.05)(p~3~\<0.001)                  16.46                 68.40(62.64,73.66)(p~4~ = 0.008)        15.60

Note: Bias =  median difference between eGFR and rGFR; P~30~ = the proportion of eGFR within 30% of rGFR; RMSE =  root mean square error.

Abbreviations: rGFR: reference glomerular filtration rate; CI: confidence interval; IQR =  the inter-quartile range of difference; C-MDRD: the Chinese modified Modification of Diet in Renal Disease equation; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; CKD-EPI~2009Scr~: serum creatinine--based CKD-EPI equation which was developed in 2009; CKD-EPI~2012cys~: cystatin C--based CKD-EPI equation which was newly developed in 2012; CKD-EPI~2012Scr-cys~: serum creatinine-- and cystatin C--based CKD-EPI equation which was newly developed in 2012.

Wilcoxon matched-pairs signed rank test was used to compare the difference between the eGFR and rGFR (p~3~); McNemar test was used to compare the P~30~ of the C-MDRD equation, MacIsaac equation, Ma equation, CKD-EPI~2012cys~ equation and CKD-EPI~2012Scr-cys~ equation against the P~30~ of CKD-EPI~2009Scr~ equation (p~4~).

Linear regression analysis also demonstrated a consistent result ([Table 5](#pone-0084688-t005){ref-type="table"}). The MacIsaac, CKD-EPI~2012Scr-cys~ and CKD-EPI~2009Scr~ equations showed better correlation, with lower slope and smaller intercept.

10.1371/journal.pone.0084688.t005

###### Regression analysis of the difference between eGFR and rGFR against the average of eGFR and rGFR.
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  All subjects            Slope of regression line with the X-axias(95% CI)   Intercept of regression line with the Y-axis(95%CI)
  ---------------------- --------------------------------------------------- -----------------------------------------------------
  C-MDRD                            0.53(0.49,0.58)(p~5~\<0.001)                      −30.91(−35.06, −26.76)(p~6~\<0.001)
  MacIsaac                          0.13(0.08,0.18)(p~5~ = 0.001)                     −12.73(−16.61, −8.85) (p~6~ = 0.4)
  Ma                                0.39(0.35,0.44)(p~5~\<0.001)                     −23.28(−26.91, −19.66)(p~6~ = 0.002)
  CKD-EPI~2009Scr~                         0.25(0.20,0.29)                                  −15.07(−18.77, −11.38)
  CKD-EPI~2012cys~                   0.21(0.16,0.26)(p~5~ = 0.3)                     −22.97(−26.55, −19.40)(p~6~ = 0.003)
  CKD-EPI~2012Scr-cys~               0.22(0.17,0.26)(p~5~ = 0.4)                      −18.73(−22.05, −15.41)(p~6~ = 0.1)

  rGFR≥60 mL/min/1.73 m^2^    Slope of regression line with the X-axias(95% CI)   Intercept of regression line with the Y-axis(95%CI)
  -------------------------- --------------------------------------------------- -----------------------------------------------------
  C-MDRD                                0.80(0.72,0.87)(p~5~\<0.001)                      −59.31(−66.71, −51.92)(p~6~\<0.001)
  MacIsaac                               0.30(0.21,0.39)(p~5~ = 0.8)                      −28.70(−36.55, −20.84)(p~6~ = 0.3)
  Ma                                    0.57(0.50,0.65)(p~5~\<0.001)                      −41.79(−48.82, −34.77)(p~6~\<0.001)
  CKD-EPI~2009Scr~                             0.32(0.24,0.40)                                  −22.95(−30.43, −15.48)
  CKD-EPI~2012cys~                       0.38(0.30,0.47)(p~5~ = 0.3)                      −38.98(−46.16, −31.79)(p~6~\<0.001)
  CKD-EPI~2012Scr-cys~                   0.31(0.23,0.38)(p~5~ = 0.8)                      −27.46(−34.30, −20.63) (p~6~ = 0.4)

  rGFR\<60 mL/min/1.73 m^2^    Slope of regression line with the X-axias(95% CI)   **Intercept of regression line with the Y-axis(95%CI)**
  --------------------------- --------------------------------------------------- ---------------------------------------------------------
  C-MDRD                                  0.73(0.63,0.84)(p~5~ = 0.4)                        −30.73(−35.79, −25.66)(p~6~ = 0.73)
  MacIsaac                               0.35(0.24,0.47)(p~5~\<0.001)                       −17.71(−22.66, −12.76)(p~6~ = 0.001)
  Ma                                      0.56(0.45,0.66)(p~5~ = 0.1)                        −24.97(−29.71, −20.23)(p~6~ = 0.2)
  CKD-EPI~2009Scr~                              0.67(0.56,0.78)                                    −29.48(−34.38, −24.59)
  CKD-EPI~2012cys~                       0.32(0.20,0.43)(p~5~\<0.001)                        −22.99(−27.62, −18.36)(p~6~ = 0.06)
  CKD-EPI~2012Scr-cys~                   0.44(0.34,0.55)(p~5~ = 0.003)                       −24.90(−29.40, −20.40)(p~6~ = 0.2)

  age\<60 y               Slope of regression line with the X-axias(95% CI)   Intercept of regression line with the Y-axis(95%CI)
  ---------------------- --------------------------------------------------- -----------------------------------------------------
  C-MDRD                            0.63(0.56,0.70)(p~5~\<0.001)                      −41.53(−48.23, −34.84)(p~6~\<0.001)
  MacIsaac                          0.19(0.11,0.26) (p~5~ = 0.3)                      −17.79(−24.23, −11.35) (p~6~ = 0.3)
  Ma                                0.44(0.38,0.50)(p~5~\<0.001)                     −27.38(−33.37, −21.39)(p~6~ = 0.002)
  CKD-EPI~2009Scr~                         0.24(0.17,0.30)                                   −13.48(−19.75, −7.22)
  CKD-EPI~2012cys~                  0.22(0.15,0.29) (p~5~ = 0.8)                      −23.06(−29.07, −17.04)(p~6~ = 0.03)
  CKD-EPI~2012Scr-cys~              0.21(0.14,0.27) (p~5~ = 0.6)                      −16.96(−22.56, −11.36)(p~6~ = 0.4)

  age≥60 y                Slope of regression line with the X-axias(95% CI)   Intercept of regression line with the Y-axis(95%CI)
  ---------------------- --------------------------------------------------- -----------------------------------------------------
  C-MDRD                            0.42(0.34,0.49)(p~5~\<0.001)                      −20.78(−25.81, −15.74)(p~6~ = 0.03)
  MacIsaac                          0.08(0.01,0.16)(p~5~ = 0.04)                       −8.53(−13.30, −3.77)(p~6~ = 0.2)
  Ma                                0.30(0.23,0.37)(p~5~ = 0.04)                      −17.17(−21.78, −12.56)(p~6~ = 0.2)
  CKD-EPI~2009Scr~                         0.19(0.12,0.26)                                   −13.18(−17.86, −8.50)
  CKD-EPI~2012cys~                  0.09(0.01,0.17)(p~5~ = 0.06)                      −17.90(−22.46, −13.33)(p~6~ = 0.2)
  CKD-EPI~2012Scr-cys~              0.13(0.06,0.20) (p~5~ = 0.2)                      −15.62(−19.85, −11.39) (p~6~ = 0.4)

Note: The slope of the regression line against the X axis stands for the bias for eGFR; the trend of accuracy for eGFR was expressed as the intercept of the regression line against the Y-axis. The difference between eGFR and rGFR was regressed against the average of eGFR and rGFR. X-axis represented the average of eGFR and rGFR. Y-axis represented the difference between eGFR and rGFR.

Abbreviations: eGFR: estimated glomerular filtration rate; rGFR: reference glomerular filtration rate; CI: confidence interval; C-MDRD: the Chinese modified Modification of Diet in Renal Disease equation; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; CKD-EPI~2009Scr~: serum creatinine--based CKD-EPI equation which was developed in 2009; CKD-EPI~2012cys~: cystatin C--based CKD-EPI equation which was newly developed in 2012; CKD-EPI~2012Scr-cys~: serum creatinine-- and cystatin C--based CKD-EPI equation which was newly developed in 2012.

ANCOVA test was used to compare the slopes (p~5~) and intercepts (p~6~) of the regression line of the C-MDRD equation, MacIsaac equation, Ma equation, CKD-EPI~2012cys~ equation and CKD-EPI~2012Scr-cys~ equation against the slope and intercept of CKD-EPI~2009Scr~ equation.

In the comparison of the diagnosis consistency of GFR stage between the eGFR and mGFR, no equation achieved substantial agreement in this study. The CKD-EPI~2012Scr-cys~ had a relatively better diagnosis consistency with a kappa value of 0.513.However, CKD-EPI~2012cys~ equation did not perform well in the whole cohort ([Table 6](#pone-0084688-t006){ref-type="table"}).

10.1371/journal.pone.0084688.t006

###### Comparison of the diagnosis consistency of GFR stage between the eGFR and rGFR.
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                                 rGFR≥90        rGFR 60--89      rGFR\<60      sum   Kappa
  -------------------------- ---------------- --------------- --------------- ----- -------
  *All subjects*                                                                    
  **C-MDRD**                                                                        
  eGFR≥90                     **197(87.9)**      169(46.9)        7(3.4)       373  
  eGFR60--89                     27(12.1)      **162(45.0)**     43(21.1)      232   0.480
  eGFR\<60                          0             29(8.1)      **154(75.5)**   183  
  **MacIsaac**                                                                      
  eGFR≥90                     **131(58.5)**      63(17.5)            0         194  
  eGFR60--89                     90(40.2)      **232(64.4)**     31(15.2)      353   0.505
  eGFR\<60                        3(1.3)         65(18.1)      **173(84.8)**   241  
  **Ma**                                                                            
  eGFR≥90                     **192(85.7)**      151(41.9)        3(1.5)       346  
  eGFR60--89                     32(14.3)      **168(46.7)**     40(19.6)      240   0.494
  eGFR\<60                          0            41(11.4)      **161(78.9)**   202  
  **CKD-EPI~2009Scr~**                                                              
  eGFR≥90                     **188(83.90)**     143(39.7)        6(2.9)       337  
  eGFR60--89                     36(16.1)      **171(47.5)**     41(20.1)      248   0.483
  eGFR\<60                          0            46(12.8)      **157(77.0)**   203  
  **CKD-EPI~2012cys~**                                                              
  eGFR≥90                     **135(60.3)**      66(18.3)            0         201  
  eGFR60--89                     79(35.3)      **177(49.2)**      16(7.8)      272   0.451
  eGFR\<60                       10(4.5)         117(32.5)     **188(92.2)**   315  
  **CKD-EPI~2012Scr-cys~**                                                          
  eGFR≥90                     **157(70.1)**      91(25.3)            0         248  
  eGFR60--89                     65(29.0)      **196(54.4)**     23(11.3)      284   0.513
  eGFR\<60                        2(0.9)         73(20.3)      **181(88.7)**   256  
  Sum                              224              360             204        788  
  *Age\<60 y*                                                                       
  **C-MDRD**                                                                        
  eGFR≥90                     **180(88.2)**      125(58.6)        4(5.3)       309  
  eGFR60--89                     24(11.8)      **83(37.6)**      16(21.3)      123   0.412
  eGFR\<60                          0             13(5.9)      **55(73.3)**    68   
  **MacIsaac**                                                                      
  eGFR≥90                     **126(61.8)**      50(22.6)            0         176  
  eGFR60--89                     75(36.8)      **147(66.5)**     16(21.3)      238   0.458
  eGFR\<60                        3(1.5)         24(10.9)      **59(78.7)**    86   
  **Ma**                                                                            
  eGFR≥90                     **178(87.3)**      120(54.3)        1(1.3)       299  
  eGFR60--89                     26(12.7)      **88(39.8)**      19(25.3)      133   0.421
  eGFR\<60                          0             13(5.9)      **55(73.3)**    68   
  **CKD-EPI~2009Scr~**                                                              
  eGFR≥90                     **176(86.3)**      122(55.2)        4(5.3)       302  
  eGFR60--89                     28(13.7)      **84(38.0)**      19(25.3)      131   0.391
  eGFR\<60                          0             15(6.8)      **52(69.3)**    67   
  **CKD-EPI~2012cys~**                                                              
  eGFR≥90                     **132(64.7)**      60(27.1)            0         192  
  eGFR60--89                     65(31.9)      **119(53.8)**     10(13.3)      194   0.423
  eGFR\<60                        7(3.4)         42(19.0)      **65(86.7)**    114  
  **CKD-EPI~2012Scr-cys~**                                                          
  eGFR≥90                     **153(75.0)**      79(35.7)            0         232  
  eGFR60--89                     49(24.0)      **124(56.1)**     14(18.7)      187   0.478
  eGFR\<60                        2(1.0)          18(8.1)      **61(81.3)**    81   
  Sum                              204              221             75         500  
  *Age≥60 y*                                                                        
  **C-MDRD**                                                                        
  eGFR≥90                      **17(85.0)**      44(31.7)         3(2.3)       64   
  eGFR60--89                     3(15.0)       **79(56.8)**      27(20.9)      109   0.482
  eGFR\<60                          0            16(11.5)      **99(76.7)**    115  
  **MacIsaac**                                                                      
  eGFR≥90                      **5(25.0)**        13(9.4)            0         18   
  eGFR60--89                     15(75.0)      **85(61.2)**      15(11.6)      115   0.481
  eGFR\<60                          0            41(29.5)      **114(88.4)**   155  
  **Ma**                                                                            
  eGFR≥90                      **14(70.0)**      31(22.3)         2(1.6)       47   
  eGFR60--89                     6(30.0)       **80(57.6)**      21(16.3)      107   0.492
  eGFR\<60                          0            28(20.1)      **106(82.2)**   134  
  **CKD-EPI~2009Scr~**                                                              
  eGFR≥90                      **12(60.0)**      21(15.1)         2(1.6)       35   
  eGFR60--89                     8(40.0)       **87(62.6)**      22(17.1)      117   0.501
  eGFR\<60                          0            31(22.3)      **105(81.4)**   136  
  **CKD-EPI~2012cys~**                                                              
  eGFR≥90                      **3(15.0)**        6(4.3)             0          9   
  eGFR60--89                     14(70.0)      **58(41.7)**       6(4.7)       78    0.349
  eGFR\<60                       3(15.0)         75(54.0)      **123(95.3)**   201  
  **CKD-EPI~2012Scr-cys~**                                                          
  eGFR≥90                      **4(20.0)**        12(8.6)            0         16   
  eGFR60--89                     16(80.0)      **72(51.8)**       9(7.0)       97    0.431
  eGFR\<60                          0            55(39.6)      **120(93.0)**   175  
  Sum                               20              139             129        288  

Note: eGFR and rGFR were given in mL/min/1.73 m^2^; bold font cells represent agreement; data were expressed as n (percentage).

Abbreviations: rGFR: reference glomerular filtration rate; eGFR: estimated glomerular filtration rate; C-MDRD: the Chinese modified Modification of Diet in Renal Disease equation; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; CKD-EPI~2009Scr~: serum creatinine--based CKD-EPI equation which was developed in 2009; CKD-EPI~2012cys~: cystatin C--based CKD-EPI equation which was newly developed in 2012; CKD-EPI~2012Scr-cys~: serum creatinine-- and cystatin C--based CKD-EPI equation which was newly developed in 2012.

Performance of six equations in subgroups {#s3c}
-----------------------------------------

In young participants, CKD-EPI~2012Scr-cys~ equation had a larger ROC^AUC^ thanCKD-EPI~2009Scr~ equation (0.883 vs. 0.829, p = 0.005) to diagnose CKD. CKD-EPI~2012cys~ equation did not perform much better than other available equations, especially in old participants. In subgroups with rGFR≥60 mL/min/1.73 m^2^ or the group with age\<60 years old, CKD-EPI~2009Scr~, Ma and C-MDRD equations continued to overestimate GFR and CKD-EPI~2012Scr-cys~ equation was unbiased whereas all equations underestimated GFR when rGFR\<60 mL/min/1.73 m^2^.Accuracy of the CKD-EPI~2012Scr-cys~ equation was superior (higher P~30~) to that of the CKD-EPI~2009Scr~ and MacIsaac equations at rGFR≥60 mL/min/1.73 m^2^ or age\<60 years old. Neither of the two new CKD-EPI equation achieved an ideal P~30~ value under the condition of rGFR\<60 mL/min/1.73 m^2^ or age ≥60 years old ([Table 4](#pone-0084688-t004){ref-type="table"}).

Linear regression analysis demonstrated a similar result that MacIsaac, CKD-EPI~2012Scr-cys~ and CKD-EPI~2009Scr~ formulae performed better than other 3 equations in young participants with normal or mildly- injured GFR.

As for the diagnosis consistency, neither of the two new equations performed well in old participants and the CKD-EPI~2012cys~ equation in particular. The CKD-EPI~2009Scr~ equation had a comparatively better diagnosis consistency with a kappa value of 0.501under the condition of age ≥60 years old ([Table 6](#pone-0084688-t006){ref-type="table"}).

Discussion {#s4}
==========

This study compared the adaptability of new formulae with other four equations in788 participants. The principal finding of the present study was that CKD-EPI~2012Scr-cys~ formula had better diagnostic value and accuracy in the entire participants, particularly in young participants with normally or mildly- injured GFR. CKD-EPI~2012cys~ equation did not perform much better than other available equations. Concurrently, CKD-EPI~2012Scr-cys~ had a better diagnosis consistency of GFR stage between the eGFR and rGFR, especially in young participants. An important issue has to be explained. In the present study, the unbalanced subgroups (the number of participants in rGFR ≥60 ml/min/1.73 m^2^ and the number of participants in age \<60 years old were much greater than the other two subgroups) might result in selective bias.

There were some other findings in this study. The MacIsaac equation, another well-behaved formula, also possessed a good diagnostic value and an impressive accuracy, even in old participants with moderately-severely injured GFR. Meanwhile, it had a fine diagnosis consistency of GFR stage between the eGFR and rGFR. It is a typical cystatin C-based equation.

It is well-known that serum creatinine is a classic kidney function indicator; however, it is easily influenced by many factors, such as body mass, dietary intake, aging, and analytic problems with assay methods [@pone.0084688-Dharnidharka1]. Consequently the serum creatinine-based equations have these inherent limitations. Cystatin C is an endogenous 13 kDa protein that is freely filtered at the glomerulus, and then almost completely reabsorbed and catabolized by proximal tubular epithelial cells with only small amounts excreted in the urine. Cystatin C generation was felt to be constant, which resulted in cystatin C-based equations having a tendency to replace creatinine-based equations for a time [@pone.0084688-Vinge1]--[@pone.0084688-Tangri1]. However, previous studies have found non-GFR determinants of cystatin C, including non-renal elimination, differences in generation among individuals, relation to such factors as inflammation, steroid use and thyroid disease [@pone.0084688-Wasn1]--[@pone.0084688-Rule1]. Thus, we cannot simply say cystatin C and cystatin C-based equations are better than serum creatinine and its formulae. Recently, Rule et al. reported serum creatinine-based equations are better than cystatin C-based ones for evaluating risk factors associated with CKD [@pone.0084688-Rule2]. Therefore, there is no perfect formula and clinicians should choose an appropriate one depending on different study objectives.

The CKD-EPI~2012Scr-cys~equation, using the combination of serum creatinine and cystatin C, provides more precise GFR estimates. The CKD-EPI working group explained that errors due to the non-GFR determinants of serum creatinine and cystatin C are independent and smaller in an equation that uses both markers than in an equation that uses only one marker. They also claimed the addition of race as a variable had improved the performance of the CKD-EPI~2012Scr-cys~equation [@pone.0084688-Inker1]. Bouvet et al. revealed that estimation of GFR using the four covariates (cystatin C, serum creatinine, body weight, and age) was less biased and more precise [@pone.0084688-Bouvet1]. Thus, equations based on combination of different markers might become the final recommendation.

There are two strengths in this study. First, most of the studies, especially the two Chinese equations (the C-MDRD equation and Ma equation), were based on the patients with CKD [@pone.0084688-Ma1], [@pone.0084688-Macdonald1], [@pone.0084688-Ma2].But eGFR always plays a role of screening the patients who might contract CKD, suggesting that those who use the equation may be healthy or with other disorders. Our study covered a proportion of subjects who might not suffer from CKD, which means we have evaluated the six famous equations in a more general population. Second, in our previous work, we investigated whether formulae possessed different diagnostic values between non-elderly and elderly subjects. Kilbride et al. tested the accuracy of the new equations in 74-year-olds or older in London [@pone.0084688-Kilbride1]. We attempted to identify the value of the new equations in both non-elderly and elderly subjects.

There are also some limitations of this study. First of all, sample size, especially the number of participants with rGFR \<30 ml/min/1.73 m^2^, is limited, and this is a single center study. Additionally, participants were all recruited from different departments of the hospital, which means rarely there was absolutely healthy population, and none of the data sets came from the population of patients with markedly reduced muscle mass or malnutrition. Thirdly, rGFR measurement by ^99^mTc-DTPA renal dynamic imaging method was still used in this study. It is, however, different from the renal clearance of Inulin used in the Mac study and ^125^I-iothalamate clearance in CKD-EPI equations. Therefore, the inconsistent rGFR may partially affect the true values. A nephrourology committee recommended double plasma clearance as the rGFR; however, before a unified rGFR can be carried out globally, this study may provide some exploratory information for clinicians and researchers. Moreover, the spectrum of disease is not uniform and the disease effect cannot be eliminated.

In summary, CKD-EPI~2012Scr-cys~ formula had better diagnostic value and accuracy in the whole cohort; however, its performance was substantially worse in old subjects with moderately-severely injured GFR. CKD-EPI~2012cys~ equation did not perform much better than other available equations. No magic formula has existed and every equation has its own characteristics. A large-scale study with many subjects and cooperating centers to develop a new formula for the general Chinese is necessary and urgent. Combination of different indicators should be recommended or more ideal endogenous indicators remain to be identified. Additionally, with the progress of medicine and the extension of human life, many countries have stepped into an aging society where elderly CKD population is rapidly expanding. We need to develop special formulae for this special population.
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